According to the results presented by Condorelli et al. [94], malignant cells from breast cancer patients are able to avoid the effect of CDK4/6 inhibition through the retinoblastoma protein mutations after exposure to palbociclib and ribociclib. This evidence concerns the gene CDK4 and breast cancer.